Search / Trial NCT00001632

Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999

Apply for Trial

Trial Information

Current as of December 10, 2023

Completed

Keywords

Hypertrophy Integrated Backscatter Cyclic Echocardiography Hypertrophic Cardiomyopathy

Description

Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease that is characterized by unexplained left ventricular hypertrophy (LVH) often associated with diastolic dysfunction and myocardial ischemia. In patients with HCM, LVH may be present at birth or it may develop during childhood and adolescence, usually during periods of rapid body growth. Currently, it is not possible to identify, using clinical or laboratory methods, those children who will develop LVH from among those with a genetic predisposition for the disease. It would therefore be beneficial to find predictors of LVH ...

Gender

All

Eligibility criteria

  • INCLUSION CRITERIA:
  • Three groups of subjects (aged 1-15 years) will be studied: normal children, children with HCM, and children that are family members of patients with HCM, but do not themselves have any evidence of LVH.
  • CONTROL GROUP (NORM GROUP):
  • Normal children under the age of 15 who have a normal two-dimensional echocardiogram will be included in the study.
  • HYPERTROPHIC CARDIOMYOPATHY GROUP (HCM GROUP):
  • Patients with HCM (unexplained LVH on two-dimensional echocardiogram) under the age of 15 will be included.
  • Family History of Hypertrophic Cardiomyopathy Group (FHCM GROUP:
  • Normal children under the age of 15 who have a first-degree relative with HCM and a normal two-dimensional echocardiogram will be included.
  • EXCLUSION CRITERIA - CONTROL GROUP:
  • Exclusion criteria will be any historical or echocardiographic evidence of congenital or valvular heart disease or any form of cardiomyopathy.
  • EXCLUSION CRITERIA - HCM GROUP:
  • Exclusion criteria will be any evidence of congenital or valvular heart disease that may explain the presence of LVH.
  • EXCLUSION CRITERIA - FHCM GROUP:
  • Exclusion criteria will be any historical or echocardiographic evidence of congenital or valvular heart disease or other form of cardiomyopathy.

Attachments

readout_NCT00001632_2023-12-10.pdf

4.5 MB

NCT00001632_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0